Analysis

Voyager Therapeutics, Inc. (VYGR) Stock Analysis

Voyager Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to VYGR.

websiteVYGR/analysis/VYGR

Voyager Therapeutics, Inc.

Voyager Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to VYGR.

Stock profile

Ticker

VYGR

Asset type

Stock

Market cap

$211.5M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Voyager Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • VYGR primary listing
  • VT6
  • A143XJ

Latest Voyager Therapeutics, Inc. news

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

- Dosing of adults with early Alzheimer’s disease in clinical trial expected H2 2026 - - Comprehensive preclinical program showed compelling pharmacology and safety profile for ...

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzhei...

- VY1706 IND application process on track for Q2 2026; clinical entry expected H2 2026 - - Data from eight ASGCT presentations highlight Voyager’s continued innovation in gene t...

Voyager Reports First Quarter 2026 Financial and Operating Results

- VY1706 and NBIB-‘233 completed IND-enabling GLP toxicology; clinical entry expected H2 2026 - - Multiple presentations at ASGCT 2026, including late breaker on VY1706 3-month ...

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 f...

- Late-breaking oral presentation: IV delivery of VY1706, a CNS penetrant AAV gene therapy for AD, demonstrates compelling pharmacology and safety in a 3-month GLP toxicology st...

Research sections

Valuation

Review valuation context for Voyager Therapeutics, Inc..

Future growth

Review future growth context for Voyager Therapeutics, Inc..

Past performance

Review past performance context for Voyager Therapeutics, Inc..

Financial health

Review financial health context for Voyager Therapeutics, Inc..

Dividend

Review dividend context for Voyager Therapeutics, Inc..

Management

Review management context for Voyager Therapeutics, Inc..

Ownership

Review ownership context for Voyager Therapeutics, Inc..

Other information

Review other information context for Voyager Therapeutics, Inc..

Community

Review community context for Voyager Therapeutics, Inc..